Next issueIssue 16 · Tue 29 Sep 

Trials

NCT07286175

Trial ID
T-ctgov-NCT07286175
Registry
ClinicalTrials.gov
NCT number
NCT07286175
Sponsor, as registered
Eli Lilly and Company
Phase
PHASE2
Indication
Bipolar Disorder
Status
RECRUITING
Start date
2025-11-24
Primary completion
2027-11
Registered countries
Argentina, Brazil, China, India, Japan, Mexico, Puerto Rico, United States
Sites
87

The sponsor's registered location list, which states intent rather than approval.

clinicaltrials.govctgov registryverified 2026-08-31

Notes on the record

Fields read from the ClinicalTrials.gov v2 API record. countries is the distinct country list across all registered locations; site_count is the number of location entries, which counts a country once per site, not once per country.

Company

Through brenipatide (LY3537031): Lilly

Cited in

Issues quoting NCT07286175 in their own text.